Scholars Central

Conference abstractPublished 23 Jul 2018

Dosimetry and efficacy analysis of 125I radioactive seeds implantation for cervical cancer with pelvic recurrent after radiotherapy

Authors: Qu Ang, Jiang Ping, Sun Haitao, Jiang Weijuan, Jiang Yuliang, Tian Suqing, Fan Jinghong, Li Xue, Li Weiyan, Wang Junjie

Peking University Third Hospital, China

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Purpose: Pelvic recurrent after radiotherapy of cervical cancer was difficult to treat. The implantation of radioactive 125I seeds was suitable for recurrent patients after radiotherapy. Therefore, we evaluated the efficacy of radioactive 125I seeds implantation for pelvic recurrent cervical cancer after radiotherapy. The dosimetric parameters affecting outcome were further analyzed to guidance therapy. Methods: A retrospective analysis was made with pelvic recurrent cervical cancer after radiotherapy from July 2005 to October 2015 in our hospital with 125I seeds implantation, under ultrasound or CT guidance. Treatment planning was performed before implantation to estimate the number, activity of the seeds. The seeds numbers ranged from 10-140 with a median numbers of 62.5 and the activity of seeds ranged from 0.5-0.8 mCi with a median activity of 0.7 mCi. Dosimetric verification was performed using CT scan immediately after 125I seeds implantation. D90, D100, V100, V150and V200 was evaluated in postoperative plan. The Kaplan-Meier method was used to calculate the local progression free survival (LPFS) rate and overall survival (OS) rate. The Log-rank test and Cox regression were used for univariate and multivariate analysis. Results: All of the 36 patients received pelvic radiotherapy previously, 13.88%(5/36) of the patients received re-irradiation. The median dose of cumulative radiotherapy was 56 (42-107) Gy EQD2. The interval time of the last radiotherapy to 125I implantation was 12 (2-60) months. 15 cases were central recurrence (41.67%, 15/36), and 21 cases were pelvic wall recurrence (58.33%, 21/36). The median follow-up time was 11.5 months (2-30 months). Vaginal fistula occurred in 1 case. No other severe adverse effects. The downgrade rate of pain was 79.2% (19/24). The short-term local control rate was 88.9% (32/36). 1-year and 2-year local progression-free survival (LPFS) rate were 34.9% and 20%, respectively. 1-year and 2-year OS rate were 52% and 19.6%, respectively. Multivariate analysis showed that the location of the recurrence volume of lesion and D90 was significantly related to LPFS (P 105 Gy and 55 Gy and 91% and 55Gy or D90>105Gy or V100>91% could significantly improve the local control.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Gynecology & Obstetrics.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalGynecology & Obstetrics
  • SubjectReproductive Medicine & Gynaecology
  • BylineArticles whose byline prints “Qu Ang”
  • BylineArticles whose byline prints “Jiang Ping”
  • BylineArticles whose byline prints “Sun Haitao”
  • BylineArticles whose byline prints “Jiang Weijuan”
  • BylineArticles whose byline prints “Jiang Yuliang”
  • BylineArticles whose byline prints “Tian Suqing”
  • BylineArticles whose byline prints “Fan Jinghong”
  • BylineArticles whose byline prints “Li Xue”